Indivior Pharmaceuticals Announces $175M Share Repurchase Deal

By Chris Stiles • Monday, May 04 12:04 • Permanent Link

Indivior Pharmaceuticals said May 4 it entered into a $175 million accelerated share repurchase agreement with Barclays Bank PLC, moving to return capital through its existing $400 million buyback authorization.

Under the deal, Indivior will pay $175 million upfront and expects to receive an initial 3,717,473 shares shortly after execution. The final share count will be set after the repurchase period ends, based on the volume-weighted average price of the stock during the term, less a discount. Final settlement is expected by the end of June 2026.

The company said the accelerated repurchase leaves $225 million of the original $400 million authorization still available. Of that balance, $100 million remains earmarked for additional repurchases. Indivior said the new buyback is not expected to affect its previously issued financial guidance. Today the company's shares have moved 0.21% to a price of $33.23. For the full picture, make sure to review Indivior Pharmaceuticals's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.